121 related articles for article (PubMed ID: 14621795)
1. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load.
Brouwer RM; Balk AH; Weimar W
Transpl Int; 1992; 5 Suppl 1():S259-61. PubMed ID: 14621795
[TBL] [Abstract][Full Text] [Related]
2. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders.
Peraira JR; Segovia J; Fuertes B; Fernández JA; Escudier JM; Salas C; Pulpón LA
Transplant Proc; 2003 Aug; 35(5):2009-10. PubMed ID: 12962879
[TBL] [Abstract][Full Text] [Related]
3. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
6. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
Birkeland SA; Hamilton-Dutoit S
Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
[TBL] [Abstract][Full Text] [Related]
7. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
Mendoza F; Kunitake H; Laks H; Odim J
Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.
Kirk AD; Cherikh WS; Ring M; Burke G; Kaufman D; Knechtle SJ; Potdar S; Shapiro R; Dharnidharka VR; Kauffman HM
Am J Transplant; 2007 Nov; 7(11):2619-25. PubMed ID: 17868060
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
[TBL] [Abstract][Full Text] [Related]
12. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
Keay S; Oldach D; Wiland A; Klassen D; Schweitzer E; Abruzzo LV; Kumar D; Bartlett S
Clin Infect Dis; 1998 Mar; 26(3):596-600. PubMed ID: 9524829
[TBL] [Abstract][Full Text] [Related]
13. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
[TBL] [Abstract][Full Text] [Related]
14. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients.
Dayton JD; Richmond ME; Weintraub RG; Shipp AT; Orjuela M; Addonizio LJ
J Heart Lung Transplant; 2011 Apr; 30(4):420-5. PubMed ID: 21147001
[TBL] [Abstract][Full Text] [Related]
15. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
16. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
Swinnen LJ; Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson MR; Heroux AL; Dizikes GJ; Pifarre R; Fisher RI
N Engl J Med; 1990 Dec; 323(25):1723-8. PubMed ID: 2100991
[TBL] [Abstract][Full Text] [Related]
17. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
[TBL] [Abstract][Full Text] [Related]
18. The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up.
McPherson I; Kirk A
Scott Med J; 2018 Feb; 63(1):3-10. PubMed ID: 29073846
[TBL] [Abstract][Full Text] [Related]
19. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
